FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092503039> ?p ?o ?g. }

• W3092503039 abstract "Recent studies have suggested that the CCR5 antagonist maraviroc (MVC) may exert an HIV-1 latency reversal effect. This study aimed at defining MVC-mediated induction of HIV-1 in three cell line latency models and in ex vivo CD4 T cells from six patients with suppressed viraemia. HIV-1 induction was evaluated in TZM-bl cells by measuring HIV-1 LTR-driven luciferase expression, and in ACH-2 and U1 latently infected cell lines by measuring cell-free (CFR) and cell-associated (CAR) HIV-1 RNA by qPCR. NF- κ B p65 was quantified in nuclear extracts by immunodetection. In ex vivo CD4 T cells, CAR, CFR and cell-associated DNA (CAD) were quantified at baseline and 1–7–14 days post-induction (T1, T7, T14). At T7 and T14, the infectivity of the CD4 T cells co-cultured with MOLT-4/CCR5 target cells was evaluated in the TZM-bl assay (TZA). Results were expressed as fold activation (FA) with respect to untreated cells. No LTR activation was observed in TZM-bl cells at any MVC concentration. NF- κ B activation was only modestly upregulated (1.6±0.4) in TZM-bl cells with 5 µM MVC. Significant FA of HIV-1 expression was only detected at 80 µM MVC, namely on HIV-1 CFR in U1 (3.1±0.9; P =0.034) and ACH-2 cells (3.9±1.4; P =0.037). CFR was only weakly stimulated at 20 µM in ACH-2 (1.7±1.0 FA) cells and at 5 µM in U1 cells (1.9±0.5 FA). Although no consistent pattern of MVC-mediated activation was observed in ex vivo experiments, substantial FA values were detected sparsely on individual samples with different parameters. Notably, in one sample, MVC stimulated all parameters at T7 (2.3±0.2 CAD, 6.8±3.7 CAR, 18.7±16.7 CFR, 7.3±0.2 TZA). In conclusion, MVC variably induces HIV-1 production in some cell line models not previously used to test its latency reversal potential. In ex vivo CD4 T cells, MVC may exert patient-specific HIV-1 induction; however, clinically relevant patterns, if any, remain to be defined." @default.
• W3092503039 created "2020-10-15" @default.
• W3092503039 creator A5002487044 @default.
• W3092503039 creator A5010371900 @default.
• W3092503039 creator A5024211201 @default.
• W3092503039 creator A5025673517 @default.
• W3092503039 creator A5031231745 @default.
• W3092503039 creator A5032859619 @default.
• W3092503039 creator A5048401909 @default.
• W3092503039 creator A5061506383 @default.
• W3092503039 creator A5066954824 @default.
• W3092503039 creator A5067155251 @default.
• W3092503039 creator A5078728203 @default.
• W3092503039 creator A5086540129 @default.
• W3092503039 creator A5090301614 @default.
• W3092503039 creator A5090552348 @default.
• W3092503039 creator A5091290072 @default.
• W3092503039 date "2021-01-01" @default.
• W3092503039 modified "2023-10-11" @default.
• W3092503039 title "Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells" @default.
• W3092503039 cites W1492921203 @default.
• W3092503039 cites W1511893663 @default.
• W3092503039 cites W1515745795 @default.
• W3092503039 cites W1827781262 @default.
• W3092503039 cites W1987424341 @default.
• W3092503039 cites W2004258189 @default.
• W3092503039 cites W2008684344 @default.
• W3092503039 cites W2030817219 @default.
• W3092503039 cites W2036533977 @default.
• W3092503039 cites W2048759154 @default.
• W3092503039 cites W2052178073 @default.
• W3092503039 cites W2054851724 @default.
• W3092503039 cites W2063028752 @default.
• W3092503039 cites W2089568674 @default.
• W3092503039 cites W2103111407 @default.
• W3092503039 cites W2112867551 @default.
• W3092503039 cites W2126903712 @default.
• W3092503039 cites W2140960367 @default.
• W3092503039 cites W2141457436 @default.
• W3092503039 cites W2152255480 @default.
• W3092503039 cites W2154786803 @default.
• W3092503039 cites W2156197349 @default.
• W3092503039 cites W2157096116 @default.
• W3092503039 cites W2286058615 @default.
• W3092503039 cites W2385064459 @default.
• W3092503039 cites W2410813747 @default.
• W3092503039 cites W2416302036 @default.
• W3092503039 cites W2416732024 @default.
• W3092503039 cites W2431451894 @default.
• W3092503039 cites W2464627058 @default.
• W3092503039 cites W2489079158 @default.
• W3092503039 cites W2614366336 @default.
• W3092503039 cites W2617725782 @default.
• W3092503039 cites W2736822140 @default.
• W3092503039 cites W2755457130 @default.
• W3092503039 cites W2763332138 @default.
• W3092503039 cites W2767594362 @default.
• W3092503039 cites W2768146006 @default.
• W3092503039 cites W2783842356 @default.
• W3092503039 cites W2785480387 @default.
• W3092503039 cites W2804663340 @default.
• W3092503039 cites W2903782576 @default.
• W3092503039 cites W2946439345 @default.
• W3092503039 cites W2978032880 @default.
• W3092503039 cites W3000848632 @default.
• W3092503039 cites W3011771003 @default.
• W3092503039 cites W37230812 @default.
• W3092503039 doi "https://doi.org/10.1099/jgv.0.001499" @default.
• W3092503039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33048041" @default.
• W3092503039 hasPublicationYear "2021" @default.
• W3092503039 type Work @default.
• W3092503039 sameAs 3092503039 @default.
• W3092503039 citedByCount "1" @default.
• W3092503039 countsByYear W30925030392023 @default.
• W3092503039 crossrefType "journal-article" @default.
• W3092503039 hasAuthorship W3092503039A5002487044 @default.
• W3092503039 hasAuthorship W3092503039A5010371900 @default.
• W3092503039 hasAuthorship W3092503039A5024211201 @default.
• W3092503039 hasAuthorship W3092503039A5025673517 @default.
• W3092503039 hasAuthorship W3092503039A5031231745 @default.
• W3092503039 hasAuthorship W3092503039A5032859619 @default.
• W3092503039 hasAuthorship W3092503039A5048401909 @default.
• W3092503039 hasAuthorship W3092503039A5061506383 @default.
• W3092503039 hasAuthorship W3092503039A5066954824 @default.
• W3092503039 hasAuthorship W3092503039A5067155251 @default.
• W3092503039 hasAuthorship W3092503039A5078728203 @default.
• W3092503039 hasAuthorship W3092503039A5086540129 @default.
• W3092503039 hasAuthorship W3092503039A5090301614 @default.
• W3092503039 hasAuthorship W3092503039A5090552348 @default.
• W3092503039 hasAuthorship W3092503039A5091290072 @default.
• W3092503039 hasBestOaLocation W30925030391 @default.
• W3092503039 hasConcept C106358424 @default.
• W3092503039 hasConcept C12823836 @default.
• W3092503039 hasConcept C13373296 @default.
• W3092503039 hasConcept C150903083 @default.
• W3092503039 hasConcept C153911025 @default.
• W3092503039 hasConcept C159047783 @default.
• W3092503039 hasConcept C203014093 @default.
• W3092503039 hasConcept C207001950 @default.
• W3092503039 hasConcept C2522874641 @default.

• next